Categories
- Clinical Practice (2)
- Current Research (22)
- Diabetes in the Press (5)
- Diabetes Technology (2)
- Diatribe (1)
- Guest Essays (2)
- Islet Sheet Updates (7)
- Press Release (1)
- Scott's Opinion (21)
- The Marat/King Dialogues (8)
- Type 1 Diabetes Classic (5)
- Uncategorized (3)
Blog Archives
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
Author Archive
Benfotiamine Pharmaceutical Therapy May be Alternative to Islets Transplants
August 17th, 2009
You are probably aware of the increasing interest in benfotiamine as an oral medication to prevent the metabolism of excess glucose in diabetics to the advanced glycation end products which are the ultimate cause of diabetic complications. This drug has a half-century record of use as an extremely safe over-the-counter remedy for alcoholic neuritis. Although data began emerging in the mid-1990s showing its capacity to block the formation of diabetic complications from excess blood sugar, it was only with M. Brownlee’s publication of its effectiveness in Nature: Medicine in February, 2003, that interest in benfotiamine really took off.
Life Expectancy of Encapsulated Islets
August 17th, 2009
I wonder if any differentially permeable membrane screen against immunological attack can work in principle. Since these devices rely on diffusion of nutrients across the membrane while nature uses vascularization to achieve cell nutrition, I suspect that encapsulated beta cells will always have a life expectancy so short that they will simply not be cost-effective, especially if they cannot provide sufficient blood glucose control to allow patients to live without chasing blood sugar levels with injected insulin.
Consequences of Cell Death in Islet Sheets?
August 17th, 2009
I wonder what happens when the encapsulated beta cells decay? Decaying tissue collapses into a wide variety of particles of different dimensions, so what ensures that they will not leak into the abdomen, which is literally a perfect medium ready to magnify even the slightest infection into instant peritonitis.
Is Partial Control Good Enough?
August 17th, 2009
If patients have to fill in the difference between the control achieved with the beta cell encapsulated implant and the physiologic levels they are striving for, the shortfall may mean that there will not be much improvement in the complications. This is clear from the fact that even slight increases in blood sugar produce measurable worsening of complications…
Potential Problems with Abdominal Site?
July 9th, 2009
If the insertion of the encapsulation into the abdomen has to be repeated every few years, have you considered the problem of scarring and surgical adhesions from these repeated procedures? The abdomen is not a paper bag that you can cut open and tape up indefinitely without consequences.
The cost of pig Islets: Too High?
July 9th, 2009
With respect to the cost, how much of this comes from the supposed need to raise the pigs used for the islet cells in sterile conditions? In European fresh cell treatment centers, patients…
Is a price of $100,000 cost effective?
July 9th, 2009
Encapsulations will certainly never be cost-effective if they cost $100,000 each, as LCT estimates, if they have to be replaced every two years, and if they are not 100% effective even while they do work.
LCT Microcapsules will be Available Soon; Islet Sheet Obsolete?
July 9th, 2009
You report that clinical studies in humans are expected to begin for your work in 2013, but you must have noticed that LCT is already claiming that it will be ready to offer its product on a commercial basis in 18 months.
